PDF(Pubmed)
Abstract：
UNASSIGNED: Accurate efficacy evaluation of bone metastases (BMs) from breast cancer (BC) is an intractable issue in clinical practice, for which solutions are urgently needed. This study aimed to investigate the utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) in the response evaluation of bone metastasis of BC.
UNASSIGNED: In total, 22 patients diagnosed with BC and BM were enrolled. These patients underwent repeated 18F-FDG PET/CT evaluations. The patients and each BM site were divided into two groups based on their response to treatment: progressive disease (PD) and nonprogressive disease (non-PD). We analyzed and compared the changes in PET and CT images, as well as the serum concentration of carcinoembryonic antigen (CEA), carbohydrate antigen 153 (CA153), alkaline phosphatase (ALP), and calcium (Ca) over the same time frame. The immunohistochemistry (IHC) of primary lesions between groups and between the primary focus and BM with high 18F-FDG uptake were compared and analyzed.
UNASSIGNED: Maximum standard uptake value (SUVmax) after therapy [area under the curve (AUC): 0.932] and Δ-value of SUVmax (AUC: 0.811) on 18F-FDG PET imaging proved significantly valuable for the efficacy of therapy outcomes related to BM lesions (P<0.05). In terms of overall evaluation of BM, age and human epidermal growth factor receptor 2 (HER2) expression were significantly lower in the PD group than in the non-PD group (P<0.05). There were marked differences in CEA after therapy, the changes of CEA, and CA153 (∆-value) between the groups (P<0.05). The SUVmax and Ca concentration after therapy and ∆-value of SUVmax, along with the levels of CA153, CEA, and ALP, were valuable indicators for evaluating the efficacy of individual BMs (P<0.05). IHC of BM in the PD group showed differences compared to primary lesions, with antigen Ki-67 being downregulated in metastatic lesions and HER2 being downregulated in a portion of BMs (2 of 6). Meanwhile, the expression of estrogen receptor (ER) and progesterone receptor (PR) remained relatively unchanged.
UNASSIGNED: 18F-FDG PET/CT confers precise assessment of the posttreatment efficacy pertaining to BM in BC. This modality facilitates the identification of poor effect lesions following extant therapies and localization for pathological assessment and may substantially contribute to evaluating therapeutic efficacy, refining treatment strategies, and predicting the disease trajectory of patients with BC and BM.
UNASSIGNED: In total, 22 patients diagnosed with BC and BM were enrolled. These patients underwent repeated 18F-FDG PET/CT evaluations. The patients and each BM site were divided into two groups based on their response to treatment: progressive disease (PD) and nonprogressive disease (non-PD). We analyzed and compared the changes in PET and CT images, as well as the serum concentration of carcinoembryonic antigen (CEA), carbohydrate antigen 153 (CA153), alkaline phosphatase (ALP), and calcium (Ca) over the same time frame. The immunohistochemistry (IHC) of primary lesions between groups and between the primary focus and BM with high 18F-FDG uptake were compared and analyzed.
UNASSIGNED: Maximum standard uptake value (SUVmax) after therapy [area under the curve (AUC): 0.932] and Δ-value of SUVmax (AUC: 0.811) on 18F-FDG PET imaging proved significantly valuable for the efficacy of therapy outcomes related to BM lesions (P<0.05). In terms of overall evaluation of BM, age and human epidermal growth factor receptor 2 (HER2) expression were significantly lower in the PD group than in the non-PD group (P<0.05). There were marked differences in CEA after therapy, the changes of CEA, and CA153 (∆-value) between the groups (P<0.05). The SUVmax and Ca concentration after therapy and ∆-value of SUVmax, along with the levels of CA153, CEA, and ALP, were valuable indicators for evaluating the efficacy of individual BMs (P<0.05). IHC of BM in the PD group showed differences compared to primary lesions, with antigen Ki-67 being downregulated in metastatic lesions and HER2 being downregulated in a portion of BMs (2 of 6). Meanwhile, the expression of estrogen receptor (ER) and progesterone receptor (PR) remained relatively unchanged.
UNASSIGNED: 18F-FDG PET/CT confers precise assessment of the posttreatment efficacy pertaining to BM in BC. This modality facilitates the identification of poor effect lesions following extant therapies and localization for pathological assessment and may substantially contribute to evaluating therapeutic efficacy, refining treatment strategies, and predicting the disease trajectory of patients with BC and BM.
摘要：
■乳腺癌（BC）骨转移（BMs）的准确疗效评估在临床实践中是一个棘手的问题，迫切需要解决方案。本研究旨在探讨18F-氟代脱氧葡萄糖正电子发射断层扫描-计算机断层扫描（18F-FDGPET/CT）在评估BC骨转移反应中的应用。
■总共，纳入22例诊断为BC和BM的患者。这些患者接受了重复的18F-FDGPET/CT评估。根据患者对治疗的反应，将患者和每个BM部位分为两组：进行性疾病（PD）和非进行性疾病（非PD）。我们分析并比较了PET和CT图像的变化，以及血清癌胚抗原（CEA）的浓度，糖类抗原153(CA153),碱性磷酸酶(ALP),和钙（Ca）在相同的时间范围内。比较并分析各组之间以及原发灶与18F-FDG高摄取BM之间的原发灶的免疫组织化学（IHC）。
■治疗后的最大标准摄取值（SUVmax）[曲线下面积（AUC）：0.932]和18F-FDGPET显像上的SUVmax的Δ值（AUC：0.811）被证明对与BM病变相关的治疗结果的有效性具有重要价值（P<0.05）。就BM的总体评价而言，PD组年龄和人表皮生长因子受体2(HER2)表达显著低于非PD组(P<0.05)。治疗后CEA有明显差异，CEA的变化，各组间CA153(Δ值)(P<0.05)。治疗后的SUVmax和Ca浓度以及SUVmax值，以及CA153，CEA，ALP,是评价个体BMs疗效的有价值的指标(P<0.05)。与原发灶相比，PD组BM的IHC显示差异，抗原Ki-67在转移性病变中下调，HER2在部分BM中下调（6个中的2个）。同时,雌激素受体（ER）和孕激素受体（PR）的表达保持相对不变。
■18F-FDGPET/CT可准确评估BC中与BM有关的治疗后疗效。这种方式有助于识别现有治疗后的不良效果病变和定位病理评估，并可能大大有助于评估治疗疗效。精炼处理策略，并预测BC和BM患者的疾病轨迹。
■总共，纳入22例诊断为BC和BM的患者。这些患者接受了重复的18F-FDGPET/CT评估。根据患者对治疗的反应，将患者和每个BM部位分为两组：进行性疾病（PD）和非进行性疾病（非PD）。我们分析并比较了PET和CT图像的变化，以及血清癌胚抗原（CEA）的浓度，糖类抗原153(CA153),碱性磷酸酶(ALP),和钙（Ca）在相同的时间范围内。比较并分析各组之间以及原发灶与18F-FDG高摄取BM之间的原发灶的免疫组织化学（IHC）。
■治疗后的最大标准摄取值（SUVmax）[曲线下面积（AUC）：0.932]和18F-FDGPET显像上的SUVmax的Δ值（AUC：0.811）被证明对与BM病变相关的治疗结果的有效性具有重要价值（P<0.05）。就BM的总体评价而言，PD组年龄和人表皮生长因子受体2(HER2)表达显著低于非PD组(P<0.05)。治疗后CEA有明显差异，CEA的变化，各组间CA153(Δ值)(P<0.05)。治疗后的SUVmax和Ca浓度以及SUVmax值，以及CA153，CEA，ALP,是评价个体BMs疗效的有价值的指标(P<0.05)。与原发灶相比，PD组BM的IHC显示差异，抗原Ki-67在转移性病变中下调，HER2在部分BM中下调（6个中的2个）。同时,雌激素受体（ER）和孕激素受体（PR）的表达保持相对不变。
■18F-FDGPET/CT可准确评估BC中与BM有关的治疗后疗效。这种方式有助于识别现有治疗后的不良效果病变和定位病理评估，并可能大大有助于评估治疗疗效。精炼处理策略，并预测BC和BM患者的疾病轨迹。
